40
Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
20
The approach of HMA plus VEN with or without BMT for all patients with AML
10
Early detection and mitigation of TCP SYN flood attacks in SDN using chi-square test
20
The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy
10
Investigating anti-D in an individual with the weak D type 2 genotype
